AbbVie Inc. logo

AbbVie Inc. (ABBV)

Market Closed
5 Dec, 20:00
NYSE NYSE
$
226. 08
-2.63
-1.15%
$
402.32B Market Cap
42.2 P/E Ratio
6.2% Div Yield
2,695,614 Volume
10.28 Eps
$ 228.71
Previous Close
Day Range
225.05 229.25
Year Range
164.39 244.81
Want to track ABBV and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 52 days
AbbVie (ABBV) Gets Nod in EU for Lymphoma Drug's Expanded Use

AbbVie (ABBV) Gets Nod in EU for Lymphoma Drug's Expanded Use

AbbVie's (ABBV) Tepkinly gets conditional approval in the EU to treat third-line patients with relapsed or refractory follicular lymphoma as a second indication.

Zacks | 1 year ago
3 High-Yield Stocks to Buy Now That Have Increased Their Dividends for 25 Years or More

3 High-Yield Stocks to Buy Now That Have Increased Their Dividends for 25 Years or More

AbbVie is a Dividend King that's poised for future growth. Enbridge offers an ultra-high dividend yield and is expanding into more areas of the energy sector.

Fool | 1 year ago
These 3 Healthcare Companies Had the Top-Selling Drugs Last Year

These 3 Healthcare Companies Had the Top-Selling Drugs Last Year

Keytruda, Humira, and Ozempic generated a combined $53 billion in sales last year. The companies that make these drugs generate a lot of their sales from them.

Fool | 1 year ago
3 High-Yielding Dividend Growth Stocks That Retirees Can Rely On for Recurring Income

3 High-Yielding Dividend Growth Stocks That Retirees Can Rely On for Recurring Income

AbbVie enables retirees to profit from both its dividend payouts and its promising growth opportunities. Verizon has a safe high-yielding dividend, which the company has been growing steadily in recent years.

Fool | 1 year ago
Lock in Gains: 3 Dividend Stocks Poised to Boost Payouts Soon

Lock in Gains: 3 Dividend Stocks Poised to Boost Payouts Soon

Investors looking for a respite from the ongoing market volatility may want to seek out dividend-paying stocks. The benefit of these stocks is that they give you an opportunity for reliable income today and into the future.

Marketbeat | 1 year ago
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It

AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It

AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks | 1 year ago
The 3 Best Stocks to Buy to Survive Another S&P 500 Crash

The 3 Best Stocks to Buy to Survive Another S&P 500 Crash

Everything looked like it was coming undone last week. As recession fears gripped the market, the S&P 500 tumbled 3% in a single day.

Investorplace | 1 year ago
Prediction: Abbvie's Dividend Payouts Will Increase in 2025

Prediction: Abbvie's Dividend Payouts Will Increase in 2025

24/7 Wall St. Insights Stocks that consistently raise their dividends offer investors huge total return potential.

247wallst | 1 year ago
3 Stocks Retirees Should Absolutely Love

3 Stocks Retirees Should Absolutely Love

AbbVie offers reliable income and solid growth prospects. Bristol Myers Squibb is a stable dividend stock to buy and hold.

Fool | 1 year ago
2 High Yielding Recession Proof Dividend Picks For A Massive Income Snowball

2 High Yielding Recession Proof Dividend Picks For A Massive Income Snowball

10,000 boomers are reaching retirement age every day. The 4% rule for retirement withdrawals may not always work due to sequence risk and market fluctuations. Building a dividend income snowball can provide a more stable retirement income, with 2 high-yielding recession-proof stock picks recommended.

Seekingalpha | 1 year ago
3 Passive Income Dividend Stocks To Buy Now

3 Passive Income Dividend Stocks To Buy Now

Seasoned investors tend to closely follow the ups and downs of the market.

247wallst | 1 year ago
How Should You Play AstraZeneca (ABBV) After Q2 Beat, View Raise?

How Should You Play AstraZeneca (ABBV) After Q2 Beat, View Raise?

AstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga should drive sales. Its pipeline is huge, with several candidates having blockbuster potential.

Zacks | 1 year ago
Loading...
Load More